CD8+ T cells are critical for oncolytic-virus mediated tumor rejection17,39,40, thus, the field has focused on boosting T cell activation by incorporating stimulatory cytokines (e.g. IL-2, IL-7, IL-12 or IFN-γ) into oncolytic vectors17,41,42, though such approaches have yielded only moderate benefit. This evidence concerns the gene IL2 and neoplasm.